EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Editas stock jumps 16% on reporting a narrower-than-expected Q4 loss and beating revenue estimates while advancing its EDIT-401 gene-editing candidate toward its first human study in 2026.